

(Downgrade)	Tra	ading Buy					
Target Price (12M, V	V)	<b>A</b>	41	,000			
Share Price (03/12/19	9, W)		36	5,000			
Expected Return				14%			
OP (18F, Wbn)				9			
Consensus OP (18F, )	Wbn)			19			
EPS Growth (18F, %)				-32.1			
Market EPS Growth (	18F, %)	)		4.7			
P/E (18F, x)				64.4			
Market P/E (18F, x)				8.9			
KOSDAQ				754.76			
Market Cap (Wbn)				546			
Shares Outstanding	(mn)			15			
Free Float (%)				68.6			
Foreign Ownership (	%)			20.6			
Beta (12M)				0.50			
52-Week Low				25,500			
52-Week High				44,950			
(%)	1M	(	6M	12M			



35.3

31.0

9.3

19.6

-13.1

1.8

Mirae Asset Daewoo Co., Ltd.

[MedTech/Healthcare Solutions]

Absolute

Relative

Choong-hyun Kim, CFA +822-3774-1740 choonghyun.kim@miraeasset.com

# **DIO Implant**

(039840 KQ)

# Big bath in 2018 = Favorable comparison in 2019

#### **4Q18 review: Earnings shock**

For 4Q18, DIO Implant reported revenue of W19.6bn (-22.3% YoY), well below the consensus. The dental IT segment performed poorly, with revenue falling 18.7% YoY on a high base of comparison (4Q17 revenue was a record W5.1bn). Implant revenue also contracted 9.2% YoY. At the operating level, the company posted a loss of W6.9bn, hurt by outsized one-off expenses, including bad debt expenses and refund liabilities.

#### Continuous expansion of digital dentistry portfolio

- 1) Digital dentistry full lineup: DIO Implant has diversified its dentistry portfolio (prosthetics, implants, and orthodontics) by expanding its equipment business (from lab-side to chairside solutions), widening its technology lead over competitors. DIO Implant's chairside solutions can allow dental implant surgeries to be completed in two hours, depending on the patient's oral condition. That said, the equipment business has been experiencing some delays in the domestic market. We expect the domestic equipment business to gain traction from 2Q19.
- **2) Overseas-driven growth to continue:** In 2019, we expect the company to see strong growth overseas (+25.9% YoY). In the core Iran market, the company is exhibiting high growth and margins on the back of its joint venture strategy. The company has also been ramping up its sales operations in the US, especially among large hospitals. We are also optimistic on China, where the company has switched its sales strategy from dealers to direct sales, as well as India, a fast-growing market.

#### Raise TP to W41,000, but downgrade to Trading Buy

We raise our target price on DIO Implant to W41,000 (from W33,000), due to our 12-month forward EPS revision. That said, we downgrade our rating to Trading Buy, as recent share price gains have reduced the upside potential to 14%. The stock is currently trading at a 12-month forward P/E of 26.5x, a premium to peers (26.2x).

DIO Implant is continuing to widen its digital dentistry technology lead over competitors with its chairside solutions and digital orthodontics technologies. However, in 2018, the company's domestic business fared poorly, as most of the expected benefits from changes in dental implant policies went to the existing market leader. In 2019, we expect earnings to improve, driven by new products (UV implants) in the domestic market and robust sales operations in North America, the biggest overseas market. We see meaningful earnings growth coming in 2H19, when sales efforts in North America are likely to bear fruit.

FY (Dec.)	12/15	12/16	12/17	12/18F	12/19F	12/20F
Revenue (Wbn)	72	88	95	91	104	129
OP (Wbn)	20	27	24	9	24	31
OP margin (%)	27.8	30.7	25.3	9.9	23.1	24.0
NP (Wbn)	9	21	10	7	19	25
EPS (W)	706	1,352	658	447	1,283	1,633
ROE (%)	15.8	22.2	8.9	5.7	14.7	16.0
P/E (x)	42.5	29.3	53.9	64.4	28.1	22.0
P/B (x)	5.3	5.0	4.0	3.1	3.4	2.9
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	0.0

Note: All figures are based on consolidated K-IFRS; NP refers to net profit attributable to controlling interests Source: Company data, Mirae Asset Daewoo Research estimates

Analysts who prepared this report are registered as research analysts in Korea but not in any other jurisdiction, including the U.S. PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES & DISCLAIMERS IN APPENDIX 1 AT THE END OF REPORT.

Table 1. 4Q18 review

(Wbn, %, %p)

				4Q18P	Grov	Growth		
	4Q17	3Q18	Preliminary	Mirae Asset Daewoo	Consensus	YoY	QoQ	
Revenue	25.2	24.0	19.6	26.1	0.0	-22.3	-18.2	
Operating profit	3.8	4.3	-6.9	4.8	0.0	TTR	TTR	
OP margin (%)	15.0	17.9	-35.0	18.4	N/A	-50.1	-53.0	
Pretax profit	-3.4	2.2	-7.6	4.1	0.0	RR	TTR	
Net profit	-4.3	2.0	-5.9	2.8	0.0	RR	TTR	

Notes: Based on K-IFRS

Source: Mirae Asset Daewoo Research estimates

Table 2. Earnings forecast revisions

(Wbn, W, %)

	Previo	ous	Revised		% ch	g.	Notes
	19F	20F	19F	20F	19F	20F	
Revenue	113.1	135.7	104.2	129.3	-7.8	-4.7	Reflects 4Q18 results
Operating profit	24.1	30.6	24.3	30.7	1.2	0.4	
Pretax profit	21.0	27.5	24.0	30.5	14.3	10.8	
Net profit	17.0	22.4	19.5	24.8	14.3	10.8	
EPS (W)	1,122	1,474	1,283	1,633	14.3	10.8	

Notes: Based on K-IFRS

Source: Mirae Asset Daewoo Research estimates


Table 3. Quarterly and annual earnings

(Wbn, %)

	1Q18	2Q18	3Q18	4Q18P	1Q19F	2Q19F	3Q19F	4Q19F	2018P	2019F	2020F
Revenue	24.2	23.2	24.0	19.6	25.6	25.0	27.7	25.8	91.0	104.2	129.3
Domestic	10.2	9.6	9.6	6.9	8.0	9.1	10.5	7.6	36.2	35.2	37.1
Iran	3.9	3.9	4.5	5.9	5.5	5.5	5.4	5.6	18.3	22.0	26.4
China	2.1	4.1	3.2	2.0	3.1	3.7	3.8	2.4	11.3	13.1	15.8
US	2.1	1.1	1.6	0.7	1.0	1.0	2.0	5.0	5.4	9.0	21.0
Other	5.9	4.6	5.1	4.2	8.1	5.7	5.9	5.3	19.8	24.9	29.0
Operating profit	7.2	4.0	4.3	-6.9	5.6	5.2	7.2	6.4	8.7	24.3	30.7
Pretax profit	8.0	4.1	2.2	-7.6	5.5	5.1	7.1	6.3	6.7	24.0	30.5
Net profit	6.9	3.7	2.0	-5.9	4.4	4.1	5.8	5.1	6.8	19.5	24.8
OP margin (%)	29.9	17.2	17.9	-35.0	21.7	20.8	26.0	24.7	9.5	23.4	23.8
Pretax margin (%)	32.9	17.8	9.3	-38.7	21.3	20.3	25.6	24.5	7.4	23.0	23.6
Net margin (%)	29.0	16.4	9.9	-30.1	17.5	16.7	21.0	20.1	7.4	18.7	19.2

Source: Mirae Asset Daewoo Research estimates

Figure 1. Ownership breakdown



Source: Mirae Asset Daewoo Research

Source: Bloomberg, Mirae Asset Daewoo Research

Figure 2. Institutional and foreign net buying vs. share price Figure 3. P/E band chart (Wbn) 100 (W) 70,000 Stock price (R) (W) Institutional investors (L) 70,000 40.0x Foreign investors (L) 80 60,000 60,000 35.0x 60 50,000 50,000 30.0x 25.0x 40,000 40 40,000 20.0x 20 30,000 30,000 0 20,000 20,000 10,000 -20 10,000 -40 0 15 17 18 19 16 15 16 17 18 19 14

Table 4. Global peer valuation

Source: Mirae Asset Daewoo Research

(Wbn)

Campanias	Market	OP margin (%)		P/E (x)		PSR (x)		ROE (%)			EV/EBITDA (x)					
Companies	сар	18	19F	20F	18	19F	20F	18	19F	20F	18	19F	20F	18	19F	20F
Straumann	14,132	25.1	26.1	26.6	46.0	35.9	30.6	9.2	8.1	7.1	23.9	25.8	25.6	24.6	26.3	22.8
Zimmer Biomet	28,083	0.4	27.6	28.1	23.2	15.6	14.6	3.1	3.1	3.0	-3.3	13.7	12.9	27.5	11.9	11.5
Dentsply Sirona	12,497	-24.0	17.2	18.6	35.0	21.4	18.8	2.8	2.7	2.7	-17.2	8.9	9.5	-	14.5	13.4
Align Technology	22,025	23.7	22.7	24.6	49.6	47.1	34.9	9.9	8.0	6.5	33.3	29.7	33.2	30.6	29.8	22.7
Danaher	101,997	17.1	21.4	22.9	33.6	26.4	23.7	4.4	4.4	4.0	9.7	11.6	14.2	17.3	19.8	17.3
Dentium	696	22.8	22.4	22.6	16.4	17.1	14.1	3.1	3.0	2.5	19.1	19.4	19.7	20.0	14.1	11.4
Osstem Implant	774	5.9	8.0	8.9	136.2	28.2	22.5	1.7	1.5	1.4	4.7	20.5	21.1	19.5	15.3	12.9
DIO Implant	546	9.6	-	-	62.8	-	-	5.4	-	-	6.7	17.4	-	19.7	-	-
Average		10.1	20.8	21.8	50.3	27.4	22.7	5.0	4.4	3.9	9.6	18.4	19.5	22.7	18.8	16.0

Source: Bloomberg, Mirae Asset Daewoo Research

Table 5. Overview of digital implants by generation

Method	Gen.	Extraoral scanning	Plaster cast	Intraoral scanning	CAD/CAM	Process	Surgical guides	Details
	1G	2D panorama	0	Х	Х	Manual	2D stent	- Extraoral images are used as references - Analog stents are made based on plaster casts
Analog	2G	3D CBCT	0	Х	Χ	Manual	2D stent	- Equivalent to 1G
Allalog	g 3G 3D CBC		0	Х	0	Milling machine/ 3D printers	nine/ 3D stent - 3D CBCT is used to fabricate guides	
Semi-digital	4G	3D CBCT	0	O (impression scanners)	0	Milling machine/ 3D printers	3D stent	Plaster casts are scanned via impression scanners     Images of extraoral structures (CBCT) are processed     via CAD/CAM
Digital	5G	3D CBCT	Х	O (oral scanners)	0	Milling machine/ 3D printers	3D stent	Oral structures are scanned through intraoral scanners     Images of extraoral structures (CBCT) are processed via CAD/CAM

Source: Mirae Asset Daewoo Research

Figure 4. Revenue breakdown by category (2018)





Figure 5. Revenue from key products



Source: Company data, Mirae Asset Daewoo Research

Source: Company data, Mirae Asset Daewoo Research

Figure 6. Revenue breakdown by region (2018)





Figure 7. Revenue in key regions




Source: Company data, Mirae Asset Daewoo Research

Source: Company data, Mirae Asset Daewoo Research

Figure 8. Medical dispute cases by category

Figure 9. Dental implant-related disputes stem mainly from procedural mistakes



Other
11%

Implant
placement
40%

Upper
prosthesis
placement
20%


Procedural
mistakes 63%
3%


Source: KCA, Mirae Asset Daewoo Research

Source: KCA, Mirae Asset Daewoo Research

Figure 10. Contributors to implant failure

Figure 11. Orthodontics market is 1.8 times larger than dental implant market







Source: KCA, Mirae Asset Daewoo Research

Source: MarketsandMarkets, Transparency Market Research, Mirae Asset Daewoo Research

Figure 12. Implants placed per 10,000 people in key countries

Figure 13. No. of dentists vs. % of dentists capable of placing implants





Source: MRG, Straumann, Mirae Asset Daewoo Research

Source: Company data, Mirae Asset Daewoo Research

## Figure 14. 3D intraoral scanner

#### Figure 15. DIOnavi ensures greater accuracy than rivals



DIOnavi. Megagen Nobel Biocare 1,000~1,200 RPM 1,000~1,200 RPM 0.1~5 degree Average 2.5 degree 0.1~15.3 degree Average 4.9 degree 0.1~1.9 degree Average of 0.4 degree

Source: 3Shape, Mirae Asset Daewoo Research

Source: Company materials, Mirae Asset Daewoo Research

Oral Scan

## Figure 16. Digital Chairside Solutions

## Figure 17. Digital Chairside Solutions: 3D oral scanner



환자만족도 증가



3Shape Trios3

Trios Design Studio



Source: Company materials, Mirae Asset Daewoo Research

진료시간 단축

Source: Company materials, Mirae Asset Daewoo Research

# Figure 18. Digital Chairside Solutions: 3D printer

# Printing **DIO Dental 3D Printer**



Source: Company materials, Mirae Asset Daewoo Research

# Figure 19. Digital Chairside Solutions: CAD/CAM

# Milling Ivoclar PrograMill One



Source: Company materials, Mirae Asset Daewoo Research

# DIO Implant (039840 KQ/Trading Buy/TP: W41,000)

## **Comprehensive Income Statement (Summarized)**

•				
(Wbn)	12/17	12/18F	12/19F	12/20F
Revenue	95	91	104	129
Cost of Sales	30	28	31	39
Gross Profit	65	63	73	90
SG&A Expenses	41	54	49	60
Operating Profit (Adj)	24	9	24	31
Operating Profit	24	9	24	31
Non-Operating Profit	-9	-2	0	0
Net Financial Income	-1	-1	0	0
Net Gain from Inv in Associates	0	0	0	0
Pretax Profit	15	7	24	31
Income Tax	4	-1	4	5
Profit from Continuing Operations	11	7	20	25
Profit from Discontinued Operations	0	0	0	0
Net Profit	11	7	20	25
Controlling Interests	10	7	19	25
Non-Controlling Interests	1	1	0	0
Total Comprehensive Profit	16	6	20	25
Controlling Interests	16	7	17	21
Non-Controlling Interests	0	-1	3	4
EBITDA	28	14	30	36
FCF (Free Cash Flow)	-9	12	10	21
EBITDA Margin (%)	29.5	15.4	28.8	27.9
Operating Profit Margin (%)	25.3	9.9	23.1	24.0
Net Profit Margin (%)	10.5	7.7	18.3	19.4

# **Statement of Financial Condition (Summarized)**

	(		,	
(Wbn)	12/17	12/18F	12/19F	12/20F
Current Assets	97	98	130	163
Cash and Cash Equivalents	8	29	39	59
AR & Other Receivables	69	53	70	81
Inventories	16	13	17	19
Other Current Assets	4	3	4	4
Non-Current Assets	79	89	83	78
Investments in Associates	0	0	0	0
Property, Plant and Equipment	74	80	74	70
Intangible Assets	1	4	4	4
Total Assets	176	187	213	242
Current Liabilities	39	34	39	43
AP & Other Payables	8	7	9	10
Short-Term Financial Liabilities	16	16	16	16
Other Current Liabilities	15	11	14	17
Non-Current Liabilities	16	26	27	27
Long-Term Financial Liabilities	13	23	23	23
Other Non-Current Liabilities	3	3	4	4
Total Liabilities	55	59	66	70
Controlling Interests	117	122	142	167
Capital Stock	8	8	8	8
Capital Surplus	80	80	80	80
Retained Earnings	34	40	59	84
Non-Controlling Interests	4	5	5	5
Stockholders' Equity	121	127	147	172

## **Cash Flows (Summarized)**

(Wbn)	12/17	12/18F	12/19F	12/20F
Cash Flows from Op Activities	6	25	10	21
Net Profit	11	7	20	25
Non-Cash Income and Expense	18	10	10	11
Depreciation	4	5	5	5
Amortization	0	0	0	0
Others	14	5	5	6
Chg in Working Capital	-13	8	-15	-10
Chg in AR & Other Receivables	-9	15	-16	-10
Chg in Inventories	-4	3	-4	-2
Chg in AP & Other Payables	-5	-3	1	1
Income Tax Paid	-9	0	-4	-5
Cash Flows from Inv Activities	-16	-14	0	0
Chg in PP&E	-15	-13	0	0
Chg in Intangible Assets	-1	-2	0	0
Chg in Financial Assets	2	0	0	0
Others	-2	1	0	0
Cash Flows from Fin Activities	11	10	0	0
Chg in Financial Liabilities	17	10	0	0
Chg in Equity	1	1	0	0
Dividends Paid	0	0	0	0
Others	-7	-1	0	0
Increase (Decrease) in Cash	1	21	10	20
Beginning Balance	7	8	29	39
Ending Balance	8	29	39	59

Source: Company data, Mirae Asset Daewoo Research estimates

## Forecasts/Valuations (Summarized)


rorecasts/valuations (Surin	rorecasts/valuations (surminarized)									
	12/17	12/18F	12/19F	12/20F						
P/E (x)	53.9	64.4	28.1	22.0						
P/CF(x)	18.2	24.5	18.2	15.3						
P/B (x)	4.0	3.1	3.4	2.9						
EV/EBITDA (x)	20.2	31.4	18.3	14.9						
EPS (W)	658	447	1,283	1,633						
CFPS (W)	1,948	1,173	1,982	2,356						
BPS (W)	8,924	9,319	10,602	12,234						
DPS (W)	0	0	0	0						
Payout ratio (%)	0.0	0.0	0.0	0.0						
Dividend Yield (%)	0.0	0.0	0.0	0.0						
Revenue Growth (%)	8.0	-4.2	14.3	24.0						
EBITDA Growth (%)	-3.4	-50.0	114.3	20.0						
Operating Profit Growth (%)	-11.1	-62.5	166.7	29.2						
EPS Growth (%)	-51.3	-32.1	187.0	27.3						
Accounts Receivable Turnover (x)	1.6	1.6	1.8	1.9						
Inventory Turnover (x)	6.5	6.3	7.1	7.2						
Accounts Payable Turnover (x)	6.6	6.5	7.0	7.1						
ROA (%)	6.8	4.0	9.8	11.0						
ROE (%)	8.9	5.7	14.7	16.0						
ROIC (%)	12.9	5.2	13.6	16.2						
Liability to Equity Ratio (%)	45.2	46.6	44.7	40.5						
Current Ratio (%)	250.8	291.3	330.0	382.4						
Net Debt to Equity Ratio (%)	16.8	7.9	0.2	-11.7						
Interest Coverage Ratio (x)	19.6	6.3	39.0	49.2						

# **APPENDIX 1**

#### **Important Disclosures & Disclaimers**

#### 2-Year Rating and Target Price History

Company (Code)	Date	Rating	<b>Target Price</b>
DIO Implant (039840)	03/12/2019	Trading Buy	41,000
	11/14/2018	Buy	33,000
	08/14/2018	Buy	44,000
	01/24/2018	Buy	51,000
	11/15/2017	Buy	47,000
	04/11/2017	Buy	41,000



Stock Ratings Industry Ratings

Buy : Relative performance of 20% or greater Overweight : Fundamentals are favorable or improving

Trading Buy : Relative performance of 10% or greater, but with volatility Neutral : Fundamentals are steady without any material changes

Hold : Relative performance of -10% and 10% Underweight : Fundamentals are unfavorable or worsening

Sell : Relative performance of -10%

Ratings and Target Price History (Share price (→), Target price (→), Not covered (■), Buy (▲), Trading Buy (■), Hold (●), Sell (◆))

- \* Our investment rating is a guide to the relative return of the stock versus the market over the next 12 months.
- \* Although it is not part of the official ratings at Mirae Asset Daewoo Co., Ltd., we may call a trading opportunity in case there is a technical or short-term material development.
- \* The target price was determined by the research analyst through valuation methods discussed in this report, in part based on the analyst's estimate of future earnings.
- \* The achievement of the target price may be impeded by risks related to the subject securities and companies, as well as general market and economic conditions.

#### **Equity Ratings Distribution & Investment Banking Services**

	Buy	Trading Buy	Hold	Sell
<b>Equity Ratings Distribution</b>	81.28%	9.63%	9.09%	0.00%
Investment Banking Services	84.61%	3.85%	11.54%	0.00%

<sup>\*</sup> Based on recommendations in the last 12-months (as of December 31, 2018)

#### **Disclosures**

As of the publication date, Mirae Asset Daewoo Co., Ltd. and/or its affiliates do not have any special interest with the subject company and do not own 1% or more of the subject company's shares outstanding.

#### **Analyst Certification**

The research analysts who prepared this report (the "Analysts") are registered with the Korea Financial Investment Association and are subject to Korean securities regulations. They are neither registered as research analysts in any other jurisdiction nor subject to the laws or regulations thereof. Each Analyst responsible for the preparation of this report certifies that (i) all views expressed in this report accurately reflect the personal views of the Analyst about any and all of the issuers and securities named in this report and (ii) no part of the compensation of the Analyst was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report. Mirae Asset Daewoo Co., Ltd. ("Mirae Asset Daewoo") policy prohibits its Analysts and members of their households from owning securities of any company in the Analyst's area of coverage, and the Analysts do not serve as an officer, director or advisory board member of the subject companies. Except as otherwise specified herein, the Analysts have not received any compensation or any other benefits from the subject companies in the past 12 months and have not been promised the same in connection with this report. Like all employees of Mirae Asset Daewoo, the Analysts receive compensation that is determined by overall firm profitability, which includes revenues from, among other business units, the institutional equities, investment banking, proprietary trading and private client division. At the time of publication of this report, the Analysts do not know or have reason to know of any actual, material conflict of interest of the Analyst or Mirae Asset Daewoo except as otherwise stated herein.

#### **Disclaimers**

This report was prepared by Mirae Asset Daewoo, a broker-dealer registered in the Republic of Korea and a member of the Korea Exchange. Information and opinions contained herein have been compiled in good faith and from sources believed to be reliable, but such information has not been independently verified and Mirae Asset Daewoo makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information and opinions contained herein or of any translation into English from the Korean language. In case of an English translation of a report prepared in the Korean language, the original Korean language report may have been made available to investors in advance of this report.

The intended recipients of this report are sophisticated institutional investors who have substantial knowledge of the local business environment, its common practices, laws and accounting principles and no person whose receipt or use of this report would violate any laws or regulations or subject Mirae Asset Daewoo or any of its affiliates to registration or licensing requirements in any jurisdiction shall receive or make any use hereof.

This report is for general information purposes only and it is not and shall not be construed as an offer or a solicitation of an offer to effect transactions in any securities or other financial instruments. The report does not constitute investment advice to any person and such person shall not be treated as a client of Mirae Asset Daewoo by virtue of receiving this report. This report does not take into account the particular investment objectives, financial

situations, or needs of individual clients. The report is not to be relied upon in substitution for the exercise of independent judgment. Information and opinions contained herein are as of the date hereof and are subject to change without notice. The price and value of the investments referred to in this report and the income from them may depreciate or appreciate, and investors may incur losses on investments. Past performance is not a guide to future performance. Future returns are not guaranteed, and a loss of original capital may occur. Mirae Asset Daewoo, its affiliates and their directors, officers, employees and agents do not accept any liability for any loss arising out of the use hereof.

Mirae Asset Daewoo may have issued other reports that are inconsistent with, and reach different conclusions from, the opinions presented in this report. The reports may reflect different assumptions, views and analytical methods of the analysts who prepared them. Mirae Asset Daewoo may make investment decisions that are inconsistent with the opinions and views expressed in this research report. Mirae Asset Daewoo, its affiliates and their directors, officers, employees and agents may have long or short positions in any of the subject securities at any time and may make a purchase or sale, or offer to make a purchase or sale, of any such securities or other financial instruments from time to time in the open market or otherwise, in each case either as principals or agents. Mirae Asset Daewoo and its affiliates may have had, or may be expecting to enter into, business relationships with the subject companies to provide investment banking, market-making or other financial services as are permitted under applicable laws and regulations.

No part of this document may be copied or reproduced in any manner or form or redistributed or published, in whole or in part, without the prior written consent of Mirae Asset Daewoo.

#### Distribution

<u>United Kingdom</u>: This report is being distributed by Mirae Asset Securities (UK) Ltd. in the United Kingdom only to (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (ii) high net worth companies and other persons to whom it may lawfully be communicated, falling within Article 49(2)(A) to (E) of the Order (all such persons together being referred to as "Relevant Persons"). This report is directed only at Relevant Persons. Any person who is not a Relevant Person should not act or rely on this report or any of its contents.

<u>United States</u>: Mirae Asset Daewoo is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This report is distributed in the U.S. by Mirae Asset Securities (USA) Inc., a member of FINRA/SIPC, to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6(b)(4) under the U.S. Securities Exchange Act of 1934, as amended. All U.S. persons that receive this document by their acceptance hereof represent and warrant that they are a major U.S. institutional investor and have not received this report under any express or implied understanding that they will direct commission income to Mirae Asset Daewoo or its affiliates. Any U.S. recipient of this document wishing to effect a transaction in any securities discussed herein should contact and place orders with Mirae Asset Securities (USA) Inc. Mirae Asset Securities (USA) Inc. accepts responsibility for the contents of this report in the U.S., subject to the terms hereof, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Mirae Asset Daewoo. The securities described in this report may not have been registered under the U.S. Securities Act of 1933, as amended, and, in such case, may not be offered or sold in the U.S. persons absent registration or an applicable exemption from the registration requirements.

Hong Kong: This report is distributed in Hong Kong by Mirae Asset Securities (HK) Limited, which is regulated by the Hong Kong Securities and Futures Commission. The contents of this report have not been reviewed by any regulatory authority in Hong Kong. This report is for distribution only to professional investors within the meaning of Part I of Schedule 1 to the Securities and Futures Ordinance of Hong Kong (Cap. 571, Laws of Hong Kong) and any rules made thereunder and may not be redistributed in whole or in part in Hong Kong to any person.

All Other Jurisdictions: Customers in all other countries who wish to effect a transaction in any securities referenced in this report should contact Mirae Asset Daewoo or its affiliates only if distribution to or use by such customer of this report would not violate applicable laws and regulations and not subject Mirae Asset Daewoo and its affiliates to any registration or licensing requirement within such jurisdiction.

#### **Mirae Asset Daewoo International Network**

Mirae Asset Daewoo Co., Ltd. (Seoul)

Global Equity Sales Team Mirae Asset Center 1 Building 26 Eulji-ro 5-gil, Jung-gu, Seoul 04539 Korea

Tel: 82-2-3774-2124

Mirae Asset Securities (USA) Inc. 810 Seventh Avenue, 37th Floor New York, NY 10019

Tel: 1-212-407-1000

PT. Mirae Asset Sekuritas Indonesia

Equity Tower Building Lt. 50
Sudirman Central Business District
Jl. Jend. Sudirman, Kav. 52-53 Jakarta Selatan
12190
Indonesia
Tel: 62-21-515-3281

Mirae Asset Securities Mongolia UTsK LLC

#406, Blue Sky Tower, Peace Avenue 17 1 Khoroo, Sukhbaatar District Ulaanbaatar 14240 Mongolia

Tel: 976-7011-0806

**Shanghai Representative Office** 

38T31, 38F, Shanghai World Financial Center 100 Century Avenue, Pudong New Area Shanghai 200120 China

Tel: 86-21-5013-6392

Mirae Asset Securities (HK) Ltd.

Suites 1109-1114, 11th Floor Two International Finance Centre 8 Finance Street, Central Hong Kong China

Mirae Asset Wealth Management (USA) Inc.

555 S. Flower Street, Suite 4410, Los Angeles, California 90071 USA

Tel: 1-213-262-3807

Tel: 852-2845-6332

Mirae Asset Securities (Singapore) Pte. Ltd.

6 Battery Road, #11-01 Singapore 049909 Republic of Singapore

Tel: 65-6671-9845

Mirae Asset Investment Advisory (Beijing) Co., Ltd

2401B, 24th Floor, East Tower, Twin Towers B12 Jianguomenwai Avenue, Chaoyang District Beijing 100022 China

Tel: 86-10-6567-9699

Ho Chi Minh Representative Office

7F, Saigon Royal Building 91 Pasteur St. District 1, Ben Nghe Ward, Ho Chi Minh City Vietnam

Tel: 84-8-3910-7715

Mirae Asset Securities (UK) Ltd.

41st Floor, Tower 42 25 Old Broad Street, London EC2N 1HQ United Kingdom

Tel: 44-20-7982-8000

Mirae Asset Wealth Management (Brazil) CCTVM

Rua Funchal, 418, 18th Floor, E-Tower Building Vila Olimpia Sao Paulo - SP 04551-060 Brasil Tel: 55-11-2789-2100

Mirae Asset Securities (Vietnam) LLC

7F, Saigon Royal Building 91 Pasteur St. District 1, Ben Nghe Ward, Ho Chi Minh City Vietnam

Tel: 84-8-3911-0633 (ext.110)

**Beijing Representative Office** 

2401A, 24th Floor, East Tower, Twin Towers B12 Jianguomenwai Avenue, Chaoyang District Beijing 100022 China

Tel: 86-10-6567-9699 (ext. 3300)